Sherrie Divito is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 86 publications with 4,277 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
77 Avenue Louis Pasteur
671 Him
Boston, MA 021155727
Telephone
617-732-5500Registry record last updated 26 Jun 2015.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20231 payment
- Janssen Biotech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
51.2%Azole Antifungal51.2%Ketoconazole100%Part D<11 patientsSensory organs
48.8%Corticosteroid48.8%Betamethasone Diprop Augmented100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Interrogating Clonal Repertoire in Drug Hypersensitivity Reactions
Brigham and Women'S Hospital
FY2026$865,521R01AI181221 - Harnessing translational research to advance understanding and clinical care in antibiotic allergy
Brigham and Women'S Hospital
FY2026$434,854UG3AI190114 - Harnessing translational research to advance understanding and clinical care in antibiotic allergy
Brigham and Women'S Hospital
FY2026$149,657UG3AI190114
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets
Journal of Clinical Investigation
2024 - Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil
New England Journal of Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
Marc Sabatine, MD
Brigham and Women's Hospital
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”